FDC Ltd
FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]
- Market Cap ₹ 6,918 Cr.
- Current Price ₹ 425
- High / Low ₹ 488 / 255
- Stock P/E 23.4
- Book Value ₹ 121
- Dividend Yield 0.00 %
- ROCE 13.2 %
- ROE 10.0 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.8% over past five years.
- Company has a low return on equity of 12.6% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
698 | 764 | 836 | 877 | 986 | 1,008 | 1,061 | 1,074 | 1,328 | 1,323 | 1,516 | 1,775 | 1,893 | |
536 | 581 | 630 | 680 | 759 | 766 | 835 | 854 | 1,033 | 999 | 1,269 | 1,520 | 1,559 | |
Operating Profit | 163 | 183 | 206 | 197 | 227 | 242 | 225 | 220 | 295 | 324 | 247 | 255 | 335 |
OPM % | 23% | 24% | 25% | 22% | 23% | 24% | 21% | 20% | 22% | 25% | 16% | 14% | 18% |
27 | 48 | 38 | 44 | 40 | 44 | 45 | 51 | 71 | 97 | 79 | 54 | 93 | |
Interest | 1 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 |
Depreciation | 18 | 28 | 25 | 38 | 34 | 35 | 35 | 33 | 37 | 38 | 37 | 39 | 39 |
Profit before tax | 170 | 201 | 217 | 201 | 232 | 250 | 234 | 236 | 325 | 380 | 285 | 266 | 384 |
Tax % | 22% | 21% | 38% | 27% | 27% | 25% | 28% | 27% | 24% | 23% | 23% | 24% | |
133 | 158 | 134 | 146 | 169 | 187 | 168 | 172 | 247 | 294 | 220 | 201 | 296 | |
EPS in Rs | 7.25 | 8.67 | 7.56 | 8.20 | 9.50 | 10.52 | 9.65 | 9.84 | 14.43 | 17.45 | 13.01 | 12.11 | 18.01 |
Dividend Payout % | 28% | 26% | 30% | 28% | 24% | 21% | 0% | 0% | 6% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 11% |
3 Years: | 10% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 4% |
5 Years: | 3% |
3 Years: | -7% |
TTM: | 66% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | 21% |
3 Years: | 16% |
1 Year: | 66% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 13% |
3 Years: | 13% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 17 | 16 |
Reserves | 670 | 762 | 823 | 912 | 1,059 | 1,246 | 1,245 | 1,416 | 1,525 | 1,705 | 1,932 | 1,964 | 1,955 |
2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 14 | 31 | 28 | 24 | |
161 | 177 | 209 | 209 | 181 | 195 | 224 | 192 | 249 | 207 | 274 | 327 | 336 | |
Total Liabilities | 851 | 959 | 1,051 | 1,140 | 1,259 | 1,459 | 1,488 | 1,625 | 1,806 | 1,943 | 2,254 | 2,335 | 2,331 |
280 | 277 | 272 | 381 | 671 | 674 | 670 | 678 | 670 | 685 | 701 | 695 | 688 | |
CWIP | 11 | 7 | 18 | 29 | 20 | 6 | 13 | 12 | 24 | 19 | 104 | 198 | 224 |
Investments | 347 | 422 | 423 | 496 | 325 | 491 | 472 | 585 | 665 | 790 | 886 | 806 | 731 |
214 | 252 | 338 | 234 | 243 | 287 | 333 | 349 | 447 | 448 | 563 | 637 | 689 | |
Total Assets | 851 | 959 | 1,051 | 1,140 | 1,259 | 1,459 | 1,488 | 1,625 | 1,806 | 1,943 | 2,254 | 2,335 | 2,331 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
140 | 149 | 149 | 127 | 171 | 153 | 148 | 104 | 239 | 210 | 162 | 165 | |
-106 | -105 | -55 | -89 | -73 | -144 | 20 | -109 | -85 | -84 | -147 | 4 | |
-58 | -62 | -75 | -47 | -97 | 0 | -169 | -0 | -142 | -126 | -10 | -180 | |
Net Cash Flow | -24 | -18 | 19 | -10 | 1 | 10 | -2 | -6 | 12 | -1 | 5 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 21 | 21 | 27 | 25 | 24 | 28 | 26 | 28 | 34 | 30 | 19 | 25 |
Inventory Days | 132 | 117 | 115 | 133 | 134 | 148 | 166 | 183 | 180 | 189 | 210 | 180 |
Days Payable | 74 | 72 | 91 | 95 | 85 | 81 | 101 | 82 | 101 | 68 | 94 | 100 |
Cash Conversion Cycle | 79 | 67 | 51 | 64 | 73 | 95 | 92 | 130 | 113 | 151 | 135 | 106 |
Working Capital Days | 25 | 25 | 3 | 12 | 22 | 24 | 28 | 44 | 42 | 49 | 46 | 49 |
ROCE % | 25% | 24% | 25% | 21% | 22% | 21% | 19% | 18% | 22% | 22% | 15% | 13% |
Documents
Announcements
- Closure of Trading Window 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 23 Feb
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 Feb
- Unaudited Financial Results For The Period Ended December 31, 2023. 7 Feb
- Board Meeting Outcome for Outcome Of Board Meeting Held On February 07, 2024 7 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Nov 2023Transcript PPT REC
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Dec 2021TranscriptPPT
-
Jun 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
May 2016TranscriptNotesPPT
Revenue Breakup
Anti-infective medicines contribute 42% of revenues, followed by gastro intestinal 24%, vitamins/ minerals 7%, ophthalmology 6%, cardiac 7%, dermatology 4% and others 11%.[1]